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Mutation of CCM2 predisposes individuals to cerebral cav-
ernous malformations, vascular abnormalities that cause sei-
zures and hemorrhagic stroke. CCM2 has been proposed to reg-
ulate the activity of RhoA for maintenance of vascular integrity.
Herein, we define a novel mechanism where the CCM2 phos-
photyrosine binding (PTB) domain binds the ubiquitin ligase
(E3) Smurf1, controlling RhoA degradation. Brain endothelial
cells with knockdown of CCM2 have increased RhoA protein
and display impaired directed cell migration. CCM2 binding of
Smurf1 increases Smurf1-mediated degradation of RhoA.
CCM2 does not significantly alter the catalytic activity of
Smurf1, nor is CCM2 a Smurf1 substrate. Rather the CCM2-
Smurf1 interaction functions to localize Smurf1 for RhoA deg-
radation. These findings provide amolecularmechanism for the
pathogenesis of cerebral cavernous malformations (CCM)
resulting from loss of CCM2-mediated localization of Smurf1,
which controls RhoA degradation required for maintenance of
normal endothelial cell physiology.
We previously characterized a scaffold-like protein named
osmosensing scaffold for MEKK3 (OSM) for its ability to bind
actin and localize to Rac-containing membrane ruffles and its
obligate requirement for p38 activation in response to hyperos-
motic stress (1). Subsequently, the gene encodingOSM,CCM2,
was found to bemutated in the human disease cerebral cavern-
ous malformations (CCM)2 (2). Cerebral cavernous malforma-
tions are vascular lesions of the central nervous system charac-
terized as clusters of dilated, thin walled blood vessels. CCM
lesions are fragile and prone to vascular leakiness and rupture,
leading to hemorrhages that cause seizure and stroke (3, 4).
Recently, CCM2 knockdown endothelial cells were shown to
have increased activation of RhoA (5), although themechanism
was not defined. Herein, we demonstrate a molecular mecha-
nism for activation of this pathway. Through a novel CCM2
PTB domain interaction with the Smurf1 homologous to the
E6-AP C terminus (HECT) domain, we now show that CCM2
binds the E3 ligase Smurf1 for the control of RhoA degradation.
EXPERIMENTAL PROCEDURES
RNAi—bEND.3 cells were purchased from ATCC. pLKO.1
and pLKO.1 CCM2 shRNA plasmids were purchased from
Open Biosystems. Lentiviral infection was done according to
the RNAi consortium protocol.
In Vitro Ubiquitination Assay—The in vitro ubiquitination
assay was done as described (6).
InVitroWoundHealingAssay—bEND.3 cells stably express-
ing pLKO.1 orCCM2 shRNAswere transducedwith pLL5.0 for
expression of green fluorescent protein. Cells were grown in
24-well dishes to a monolayer and imaged on the BD Bio-
sciences Pathway high content imager. Wounds were imaged
every 15 min for 16 h on a 10 objective. The percentage of
wound healing was determined as the area of the wound
remaining after 16 h divided by the initial area of the wound
(ImageJ).
RESULTS AND DISCUSSION
CCM2 Binds Smurf1—We have previously demonstrated
thatMEKK3, a Ste11-likeMAP3K, regulates the p38 pathway in
mammalian cells in response to hyperosmolarity (1). MEKK3 is
highly homologous toMEKK2, and both have a conserved pro-
line-rich motif that, in MEKK2, has been shown to bind the E3
ubiquitin ligase Smurf1 (7). Therefore, we asked whether
Smurf1 was found in the CCMprotein complex (8), possibly by
binding to the PY motif of MEKK3. Cells stably expressing
FLAG-taggedwild type CCM2or a CCM2PTB domainmutant
(CCM2-F217A) that is unable to bind NPXY motifs in target
proteins were used in co-immunoprecipitation assays to define
endogenous proteins that bind to the CCM protein complex
(8). Fig. 1A shows that endogenous Smurf1 co-immunoprecipi-
tated with FLAG-CCM2 but not CCM2-F217A, indicating that
Smurf1 associates with the CCM2 protein complex in a PTB
domain-dependent manner.
MEKK3 binds CCM2 independent of the CCM2 PTB
domain (8), suggesting that Smurf1 association with the CCM
complex is independent of MEKK3. However, we found that
Smurf1 was also able to associate withMEKK3 by co-immuno-
precipitation (supplemental Fig. 1A). Using purified proteins,
CCM2 and MEKK3 both directly bind GST-Smurf1 (Fig. 1B
and supplemental Fig. 1B). From this we conclude that Smurf1
and CCM2 are binding partners both in vivo and in vitro.
CCM2 Binds Smurf1 via a PTB Domain-HECT Domain
Interaction—Smurf1 is a member of the NEDD4 family of E3
ligases, which have a common domain structure of anN-termi-
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nal C2 domain followed bymultipleWWdomains and a C-ter-
minal HECT domain (9). Smurf1 constructs were generated
that encoded either the N-terminal moiety of Smurf1 (FLAG-
Smurf1 HECT containing the C2 and WW domains) or the
C-terminal moiety of Smurf1 (FLAG-Smurf1 HECT encoding
only the HECT domain). Co-expression of the Smurf1moieties
with CCM2 indicated that CCM2 predominantly bound the
HECT domain with little binding to the N-terminal portion of
Smurf1 (Fig. 1C), indicating thatCCM2was binding specifically
to the HECT domain. Consistent with this, the HECT domain
of Smurf1 was sufficient to bind CCM2 by co-immunoprecipi-
tation (supplemental Fig. 1C). To our knowledge, this is the first
demonstration of a PTB domain-HECT domain interaction.
The consensus PTB-binding motif is Asn-Pro-Xaa-Tyr
(NPXY), whereXaa andX represent any amino acid (10). Exam-
ination of the amino acid sequence of the Smurf1 HECT
domain identified an NPYY motif (amino acids 457–460) that
is also conserved in the Smurf2 HECT domain. As would be
predicted, CCM2 can bind Smurf1 or Smurf2 (supplemental
Fig. 1D). The tyrosine of the NPXY motif is critical for interac-
tion of binding partners with many PTB domains (10). Muta-
tion of Tyr-460 alone within the Smurf1 NPYYmotif to alanine
had little effect on interaction with CCM2 by co-immunopre-
cipitation (data not shown). Engineering combinations of
mutations involving two mutations within the NPYY motif of
Smurf1 determined that N457A/Y460A (APYA) had a partial
inhibition of association, whereasmutation at residues Tyr-459
and Tyr-460 (NPAA, referred to as Smurf1 YY-AA below)
caused a total loss of association with CCM2 (Fig. 1D). These
results indicate that the PTB domain of CCM2 requires the
NPYY motif within the Smurf1 HECT domain for binding.
CCM2 Is Not a Smurf1 Substrate, nor Does It Affect Smurf1
Catalytic Activity—To determine the function of the CCM2-
Smurf1 interaction, we first examined whether CCM2 was a
Smurf1 substrate. In cells expressing Smurf1 WT or the cata-
lytically inactive Smurf1 C699A, there was no change in abun-
dance of CCM2 relative to control transfected cells, although
we did detect loss of known Smurf1 substrates MEKK2 and
RhoA (Fig. 2A) (7, 11). As theHECTdomain catalyzes the ubiq-
uitination of Smurf1 substrates, binding of CCM2 to the
Smurf1 HECT domain could therefore regulate the catalytic
activity of Smurf1. Based on in vitro ubiquitination assays, we
were not able to detect any substantial change in Smurf1 cata-
lytic activity in the presence of CCM2 (Fig. 2, B and C). These
results indicate that CCM2 is not a substrate for Smurf1, nor
does it regulate Smurf1 catalytic activity.
CCM2Regulates RhoADegradation—To determine whether
CCM2 regulates degradation of Smurf1 substrates, we utilized
RNAi. Using a lentivirus-based shRNA system, brainmicrovas-
cular endothelial cells (bEND.3) were infected with either a
control vector (pLKO.1) or two independent CCM2 shRNA
vectors. These shRNA vectors were found to be effective at
knocking down CCM2 expression by 90% (supplemental Fig.
2A). Cells expressing shRNA for CCM2 had increased levels of
RhoA as determined by immunoblotting (Fig. 3A). These cells
did not show a significant increase in RhoA message (supple-
mental Fig. 2B), suggesting that the increased RhoA detected
was occurring post-transcriptionally. Importantly, knockdown
of CCM2 did not affect abundance of the Smurf1 substrate
MEKK2, the Smurf1-interacting protein MEKK3, or the
GTPase Rac1 (Fig. 3A). These findings indicate that loss of
CCM2 expression selectively facilitates degradation of RhoA
but not other Smurf1 substrates such as MEKK2.
To determine whether CCM2 facilitates Smurf1-mediated
degradation of RhoA, we expressed increasing amounts of
CCM2 in combination with Smurf1 and RhoA (Fig. 3B). Cells
expressing Smurf1 C699A and increasing amounts of CCM2
FIGURE 1. Smurf1 binds CCM2 via a novel PTB domain-HECT domain
interaction. A, RAW264.7 stable cell lines expressing empty vector, FLAG-
CCM2, or FLAG-CCM2 F217A were lysed and incubated with anti-FLAG-
coated Sepharose beads. The associated endogenous Smurf1 was examined
by Western blot using anti-Smurf1 antibody. IP, immunoprecipitation. B, the
Smurf1-CCM2 interaction is direct. Purified GST or GST-Smurf1 was incubated
with purified His-CCM2, and associating CCM2 was determined by Western
blot using anti-CCM2 antibody. C, cells expressing HA-CCM2 with FLAG-
Smurf1 C699A (a catalytically inactive mutant of Smurf1 used to examine
protein-protein interactions), FLAG-Smurf1HECT, or FLAG-Smurf1 HECT
were lysed and immunoprecipitated with anti-HA antibody. The associating
proteins were determined by Western blot with anti-FLAG antibody. D, an
NPYY motif within the HECT domain of Smurf1 is responsible for interaction
with CCM2. Cells expressing HA-CCM2 and FLAG-Smurf1 C699A, FLAG-
Smurf1 N457A/Y460A/C699A, FLAG-Smurf1 P458A/Y460A/C699A, or FLAG-
Smurf1 Y459A/Y460A/C699A were lysed and immunoprecipitated with anti-
FLAG antibody. Associated HA-CCM2 was determined by Western blot using
anti-HA antibody.
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had little effect on RhoA levels. In contrast, increasing
amounts of CCM2 in the presence of wild type Smurf1 led to
significant loss of RhoA protein, consistent with CCM2 reg-
ulating Smurf1-dependent RhoA degradation.
CCM2 Regulates Endothelial Cell Migration—Consistent
with our observation that CCM2 was capable of regulating
RhoA levels, knockdown of CCM2 led to increased stress fiber
formation in brain endothelial cells. CCM2 knockdown cells
had increased association of phosphorylatedmyosin light chain
2 with these stress fibers. Treatment of CCM2 knockdown cells
with the Rho kinase (ROCK) inhibitor Y-27632 was able to
reverse this effect (supplemental Fig. 2, C–E). To determine
whether these cytoskeletal changes impacted cell migration, we
performed wound healing assays. bEND.3 cells expressing a
control vectorwere capable of healing 50%of thewound in 16h;
however, cells lacking CCM2 were only capable of closing 25%
of the wound in the same period of time (Fig. 3, C and D). This
finding is consistent with increased RhoA abundance as RhoA
degradation is necessary for cytoskeletal turnover and migra-
tion. The defects we observed in CCM2 knockdown cells were
not limited to migration. We observed increased permeability
of endothelial cell monolayers and decreased tubule formation
in CCM2 knockdown cells (supplemental Fig. 3). Therefore, in
addition to migration, endothelial tubule formation and main-
tenance of a permeability barrier require CCM2.
Co-expression of CCM2 and Smurf1 Leads to Cell Roun-
ding—When expressed in COS-7 cells, CCM2 was localized in
the cytoplasm with enhanced localization at the plasma mem-
brane (Fig. 4A). Smurf1 was also localized at the cell periphery,
a function of the C2 domain of NEDD4 family members (12).
When co-expressed, Smurf1 and CCM2 co-localized to the
plasma membrane and induced a dramatic rounding morphol-
ogy (Fig. 4B). Cell roundingwas not observed in cells expressing
CCM2 or Smurf1 alone nor in cells expressing CCM2 and
Smurf1 C699A (Fig. 4,A andC). Furthermore, cells co-express-
ing CCM2 and Smurf1 YY-AA, which cannot bind CCM2, did
not show a cell-rounding phenotype (Fig. 4D), suggesting that
the CCM2-Smurf1 complex is regulating the cytoskeleton.
Importantly, cell spreading was rescued with expression of
exogenous RhoA (Fig. 4, E and F), signifying that cell rounding
was due to loss of RhoA protein.
CCM2 Localizes Smurf1 by Binding the HECT Domain—We
have shown that CCM2 regulates localization of the MEKK3-
MKK3-p38 signaling module and localization of KRIT1 (1, 13).
Therefore, we hypothesized that CCM2 regulates Smurf1 local-
ization. The C2 domain of Smurf1 localizes Smurf1 to the
plasma membrane. Therefore, CCM2 binding is not required
formembrane localization of Smurf1 but would be predicted to
localize Smurf1 to CCM2 protein complexes. As expected, the
Smurf1 HECT domain, when expressed alone, was not able
to localize to the cell membrane because it lacks a C2 domain
(Fig. 4G). Expression of CCM2 with the Smurf1 HECT
domain resulted in relocalization of the Smurf1 HECT
domain to the plasma membrane, where it co-localized with
CCM2 (Fig. 4G). Thus, the CCM2 PTB-Smurf1 HECT
domain interaction localizes Smurf1 to CCM2 complexes
primarily at the cell periphery.
The significance of our work is, in part, the knockdown of
CCM2 in a brain microvascular endothelial cell line, bEND.3.
Endothelial cells lacking CCM2 expression are defective in cell
migration, permeability, and tubule formation. bEND.3 cells
display an increase in RhoA abundance, predictably leading to
increased signaling via the ROCK pathway. Indeed, the impor-
tance of ROCK signaling in endothelial cells has been recog-
nized. Subsequent phosphorylation ofMLC2 results in actomy-
osin contractility, loss of cell-to-cell contact, and increased
permeability (14). We show that CCM2 knockdown leads to
increased abundance of RhoA and stress fibers as well as
FIGURE 2. CCM2 is not a Smurf1 substrate, nor does it impact Smurf1 catalytic activity. A, cells expressing HA-CCM2, HA-MEKK2, Myc-RhoA, FLAG-Smurf1
C699A, or FLAG-Smurf1 WT were lysed, and steady-state levels of HA-CCM2, HA-MEKK2, or Myc-RhoA were determined by Western blot. B, cells expressing
FLAG-Smurf1 C699A, FLAG-Smurf1 WT, or HA-CCM2 were lysed, and FLAG-Smurf1 proteins were immunopurified (IP). The immunopurified FLAG-Smurf1 or
FLAG-Smurf1 C699A was subsequently used for an in vitro ubiquitination assay. C, cells expressing FLAG-Smurf1 C699A, FLAG-Smurf1 WT, or FLAG-Smurf1
YY-AA were lysed, and immunopurified FLAG-Smurf1 was used for in vitro ubiquitination.
ACCELERATED PUBLICATION: CCM2 Control of Smurf1
MAY 15, 2009 • VOLUME 284 • NUMBER 20 JOURNAL OF BIOLOGICAL CHEMISTRY 13303
increased phosphorylated MLC2 associated with stress fibers.
Further, co-expression of CCM2 and Smurf1 led to cell round-
ing, likely due to dramatic loss of RhoA and cytoskeletal
collapse.
Recent work has shown that CCM2 is a negative regulator
of RhoA signaling in human umbilical vein endothelial cells
(5); however, the molecular mechanism was not determined.
We also provide evidence for activation of this pathway,
although we observed a decrease in directed cell migration in
bEND.3 cells, a response not observed with human umbilical
vein endothelial cells. This suggests variability in endothelial
cell physiology between these two cell types. Taken together,
these studies strongly suggest that defective RhoA regulation
is a significant contributor to the pathogenesis of CCM.
We now provide the mechanism of increased RhoA signal-
ing associated with loss of CCM2. For the first time, we show
that CCM2 associates with Smurf1 to regulate the degrada-
tion of the GTPase RhoA. Further, we have characterized a
novel interaction between the CCM2 PTB domain and the
Smurf1 HECT domain. Although the CCM2 interaction with
Smurf1 does not regulate the catalytic activity of Smurf1 nor
act to recruit CCM2 as a Smurf1 substrate, this interaction
FIGURE 3. CCM2 regulates Smurf1-medated RhoA abundance and migration of brain endothelial cells. A, bEND.3 cells expressing pLKO.1 or CCM2
shRNAs were lysed, and the abundance of RhoA, Rac1, MEKK2, and MEKK3 was analyzed by Western blot. Erk2 was measured as a loading control. -Fold
change was calculated by determining the RhoA intensity relative to the Erk2 intensity for that sample standardized to the RhoA/Erk2 ratio for cells
expressing pLKO.1. The line denotes where lanes were removed for clarity. B, HEK293 cells were transfected with Myc-RhoA, FLAG-Smurf1 WT, FLAG-
Smurf1 C699A, and increasing amounts of HA-CCM2. Cells were subsequently lysed and analyzed by Western blot. C, bEND.3 cells grown to confluency
were subjected to an in vitro wound healing assay. Cells were imaged every 15 min for 16 h. The paths taken by cells (green) expressing either pLKO.1 or
CCM2 shRNAs demonstrates decreased migration in CCM2 knockdown cells. The starting point of the cell is shown in blue, and its final location is shown
in red. D, quantitation of in vitro wound healing assays. Cells lacking CCM2 expression are less able to close a wound as measured by the percentage of
wound closure. Error bars, *, p  0.02.
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plays a role in localization of Smurf1 to promote degradation
of RhoA.
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FIGURE 4. Expression of Smurf1 WT and CCM2 leads to cell morphology changes. A, COS-7 cells expressing HA-CCM2, FLAG-Smurf1 WT, or FLAG-Smurf1
YY-AA were fixed and stained with anti-HA antibody or anti-FLAG antibody. B, COS-7 cells expressing HA-CCM2 and Smurf WT display cell rounding, whereas
cells expressing HA-CCM2 and FLAG-Smurf1 C699A (C) or HA-CCM2 and FLAG-Smurf1 YY-AA (D) do not. E, expression of exogenous RhoA (CFP-RhoA WT, where
CFP indicates cyan fluorescent protein) rescues cell spreading in cells expressing CCM2, Smurf1 WT, and RhoA WT. F, quantitation of cell spreading. The area of
cell spreading was measured using ImageJ, n  20. Error bars represent S.E. *, p  0.0001 relative to cells expressing CCM2 alone. G, the Smurf1 HECT domain
does not localize to the plasma membrane, and CCM2 recruits the Smurf1 HECT domain to the plasma membrane. COS-7 cells expressing HA-CCM2, FLAG-
Smurf1 C699A, or FLAG-Smurf1 HECT were fixed and stained with anti-FLAG and anti-HA antibodies.
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